PGS Catalog - Tanha HM, HGG Adv (2025) (Publication)

Polygenic Score ID & Name	PGS Publication ID (PGP)	Reported Trait	Mapped Trait(s) (Ontology)	Number of Variants	Ancestry distribution GWAS Dev Eval	Scoring File (FTP Link)
PGS005238 (LDpred2)	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Prostate carcinoma	prostate carcinoma	964,607		https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005238/ScoringFiles/PGS005238.txt.gz
PGS005239 (PRS-CS)	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Prostate carcinoma	prostate carcinoma	943,048		https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005239/ScoringFiles/PGS005239.txt.gz
PGS005237 (SCT)	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Prostate carcinoma	prostate carcinoma	517,551		https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005237/ScoringFiles/PGS005237.txt.gz
PGS005241 (SBayesRC)	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Prostate carcinoma	prostate carcinoma	3,802,635	-	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005241/ScoringFiles/PGS005241.txt.gz
PGS005240 (SBayesR)	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Prostate carcinoma	prostate carcinoma	904,103	-	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005240/ScoringFiles/PGS005240.txt.gz

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance Metric ID (PPM)	Evaluated Score	PGS Sample Set ID (PSS)	Performance Source	Trait	PGS Effect Sizes (per SD change)	Classification Metrics	Other Metrics	Covariates Included in the Model	PGS Performance: Other Relevant Information
PPM022676	PGS005238 (LDpred2)	PSS012055\| African Ancestry\| 3,193 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.592 [0.533, 0.651]	—	-	—
PPM022677	PGS005239 (PRS-CS)	PSS012055\| African Ancestry\| 3,193 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.596 [0.538, 0.655]	—	-	—
PPM022670	PGS005237 (SCT)	PSS012056\| European Ancestry\| 184,010 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.683 [0.674, 0.693]	—	-	—
PPM022671	PGS005238 (LDpred2)	PSS012056\| European Ancestry\| 184,010 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.698 [0.689, 0.707]	—	-	—
PPM022672	PGS005239 (PRS-CS)	PSS012056\| European Ancestry\| 184,010 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.685 [0.676, 0.695]	—	-	—
PPM022673	PGS005240 (SBayesR)	PSS012056\| European Ancestry\| 184,010 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.694 [0.685, 0.703]	—	-	—
PPM022674	PGS005241 (SBayesRC)	PSS012056\| European Ancestry\| 184,010 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.644 [0.634, 0.653]	—	-	—
PPM022675	PGS005237 (SCT)	PSS012055\| African Ancestry\| 3,193 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.578 [0.518, 0.638]	—	-	—
PPM022678	PGS005240 (SBayesR)	PSS012055\| African Ancestry\| 3,193 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.553 [0.495, 0.61]	—	-	—
PPM022679	PGS005241 (SBayesRC)	PSS012055\| African Ancestry\| 3,193 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.55 [0.483, 0.616]	—	-	—
PPM022680	PGS005237 (SCT)	PSS012057\| South Asian Ancestry\| 5,097 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.726 [0.63, 0.821]	—	-	—
PPM022681	PGS005238 (LDpred2)	PSS012057\| South Asian Ancestry\| 5,097 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.742 [0.664, 0.82]	—	-	—
PPM022682	PGS005239 (PRS-CS)	PSS012057\| South Asian Ancestry\| 5,097 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.709 [0.623, 0.795]	—	-	—
PPM022683	PGS005240 (SBayesR)	PSS012057\| South Asian Ancestry\| 5,097 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.699 [0.615, 0.784]	—	-	—
PPM022685	PGS005237 (SCT)	PSS012054\| European Ancestry\| 6,791 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.668 [0.635, 0.701]	—	-	—
PPM022686	PGS005238 (LDpred2)	PSS012054\| European Ancestry\| 6,791 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.702 [0.67, 0.733]	—	-	—
PPM022687	PGS005239 (PRS-CS)	PSS012054\| European Ancestry\| 6,791 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.678 [0.646, 0.71]	—	-	—
PPM022688	PGS005240 (SBayesR)	PSS012054\| European Ancestry\| 6,791 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.699 [0.668, 0.73]	—	-	—
PPM022689	PGS005241 (SBayesRC)	PSS012054\| European Ancestry\| 6,791 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.64 [0.606, 0.674]	—	-	—
PPM022690	PGS005237 (SCT)	PSS012053\| European Ancestry\| 1,809 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.691 [0.66, 0.723]	—	-	—
PPM022691	PGS005238 (LDpred2)	PSS012053\| European Ancestry\| 1,809 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.717 [0.687, 0.747]	—	-	—
PPM022692	PGS005239 (PRS-CS)	PSS012053\| European Ancestry\| 1,809 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.704 [0.674, 0.735]	—	-	—
PPM022694	PGS005241 (SBayesRC)	PSS012053\| European Ancestry\| 1,809 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.694 [0.663, 0.725]	—	-	—
PPM022695	PGS005237 (SCT)	PSS012056\| European Ancestry\| 184,010 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.781 [0.774, 0.788]	—	Age-specific absolute risk adjusted by PGS relative risk	—
PPM022696	PGS005238 (LDpred2)	PSS012056\| European Ancestry\| 184,010 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.789 [0.782, 0.796]	—	Age-specific absolute risk adjusted by PGS relative risk	—
PPM022697	PGS005239 (PRS-CS)	PSS012056\| European Ancestry\| 184,010 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.782 [0.775, 0.789]	—	Age-specific absolute risk adjusted by PGS relative risk	—
PPM022699	PGS005241 (SBayesRC)	PSS012056\| European Ancestry\| 184,010 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.758 [0.751, 0.766]	—	Age-specific absolute risk adjusted by PGS relative risk	—
PPM022700	PGS005237 (SCT)	PSS012057\| South Asian Ancestry\| 5,097 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.845 [0.793, 0.897]	—	Age-specific absolute risk adjusted by PGS relative risk	—
PPM022701	PGS005238 (LDpred2)	PSS012057\| South Asian Ancestry\| 5,097 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.842 [0.79, 0.894]	—	Age-specific absolute risk adjusted by PGS relative risk	—
PPM022702	PGS005239 (PRS-CS)	PSS012057\| South Asian Ancestry\| 5,097 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.834 [0.778, 0.889]	—	Age-specific absolute risk adjusted by PGS relative risk	—
PPM022703	PGS005240 (SBayesR)	PSS012057\| South Asian Ancestry\| 5,097 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.836 [0.78, 0.893]	—	Age-specific absolute risk adjusted by PGS relative risk	—
PPM022704	PGS005241 (SBayesRC)	PSS012057\| South Asian Ancestry\| 5,097 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.805 [0.743, 0.868]	—	Age-specific absolute risk adjusted by PGS relative risk	—
PPM022705	PGS005237 (SCT)	PSS012055\| African Ancestry\| 3,193 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.796 [0.756, 0.835]	—	Age-specific absolute risk adjusted by PGS relative risk	—
PPM022706	PGS005238 (LDpred2)	PSS012055\| African Ancestry\| 3,193 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.798 [0.759, 0.838]	—	Age-specific absolute risk adjusted by PGS relative risk	—
PPM022707	PGS005239 (PRS-CS)	PSS012055\| African Ancestry\| 3,193 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.8 [0.761, 0.84]	—	Age-specific absolute risk adjusted by PGS relative risk	—
PPM022708	PGS005240 (SBayesR)	PSS012055\| African Ancestry\| 3,193 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.793 [0.755, 0.831]	—	Age-specific absolute risk adjusted by PGS relative risk	—
PPM022709	PGS005241 (SBayesRC)	PSS012055\| African Ancestry\| 3,193 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.788 [0.747, 0.829]	—	Age-specific absolute risk adjusted by PGS relative risk	—
PPM022710	PGS005237 (SCT)	PSS012054\| European Ancestry\| 6,791 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.715 [0.686, 0.744]	—	Age-specific absolute risk adjusted by PGS relative risk	—
PPM022712	PGS005239 (PRS-CS)	PSS012054\| European Ancestry\| 6,791 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.722 [0.694, 0.751]	—	Age-specific absolute risk adjusted by PGS relative risk	—
PPM022713	PGS005240 (SBayesR)	PSS012054\| European Ancestry\| 6,791 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.736 [0.709, 0.763]	—	Age-specific absolute risk adjusted by PGS relative risk	—
PPM022714	PGS005241 (SBayesRC)	PSS012054\| European Ancestry\| 6,791 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.689 [0.661, 0.718]	—	Age-specific absolute risk adjusted by PGS relative risk	—
PPM022715	PGS005237 (SCT)	PSS012053\| European Ancestry\| 1,809 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.706 [0.676, 0.736]	—	Age-specific absolute risk adjusted by PGS relative risk	—
PPM022716	PGS005238 (LDpred2)	PSS012053\| European Ancestry\| 1,809 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.725 [0.696, 0.754]	—	Age-specific absolute risk adjusted by PGS relative risk	—
PPM022717	PGS005239 (PRS-CS)	PSS012053\| European Ancestry\| 1,809 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.712 [0.682, 0.741]	—	Age-specific absolute risk adjusted by PGS relative risk	—
PPM022718	PGS005240 (SBayesR)	PSS012053\| European Ancestry\| 1,809 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.713 [0.683, 0.742]	—	Age-specific absolute risk adjusted by PGS relative risk	—
PPM022719	PGS005241 (SBayesRC)	PSS012053\| European Ancestry\| 1,809 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.705 [0.675, 0.736]	—	Age-specific absolute risk adjusted by PGS relative risk	—
PPM022684	PGS005241 (SBayesRC)	PSS012057\| South Asian Ancestry\| 5,097 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.594 [0.486, 0.703]	—	-	—
PPM022693	PGS005240 (SBayesR)	PSS012053\| European Ancestry\| 1,809 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.702 [0.672, 0.732]	—	-	—
PPM022698	PGS005240 (SBayesR)	PSS012056\| European Ancestry\| 184,010 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.787 [0.78, 0.794]	—	Age-specific absolute risk adjusted by PGS relative risk	—
PPM022711	PGS005238 (LDpred2)	PSS012054\| European Ancestry\| 6,791 individuals	PGP000741 \| Tanha HM et al. HGG Adv (2025)	Reported Trait: 5-year incident prostate cancer	—	AUROC: 0.741 [0.714, 0.768]	—	Age-specific absolute risk adjusted by PGS relative risk	—

Evaluated Samples

PGS Sample Set ID (PSS)	Phenotype Definitions and Methods	Participant Follow-up Time	Sample Numbers	Sample Ancestry	Additional Ancestry Description	Cohort(s)	Additional Sample/Cohort Information
PSS012053	Linked cancer registry records were used to identify participants diagnosed with incident malignant neoplasm of the prostate (ICD-10 code: C61; ICD-9 code: 185) within five years of prediction baseline.	—	1,809 individuals [ 327 cases , 1,482 controls ] , 100.0 % Male samples	European	PC1-PC4 values ±3s.d. from the 1000G European cluster	MCCS	MCCS had a case/sub-cohort design, leading to a higher proportion of cases
PSS012054	Linked cancer registry records were used to identify participants diagnosed with incident malignant neoplasm of the prostate (ICD-10 code: C61; ICD-9 code: 185) within five years of prediction baseline.	—	6,791 individuals [ 269 cases , 6,522 controls ] , 100.0 % Male samples	European	PC1-PC4 values ±3s.d. from the 1000G European cluster	QSKIN	—
PSS012055	Linked cancer registry records were used to identify participants diagnosed with incident malignant neoplasm of the prostate (ICD-10 code: C61; ICD-9 code: 185) within five years of prediction baseline.	—	3,193 individuals [ 82 cases , 3,111 controls ] , 100.0 % Male samples	African American or Afro-Caribbean	AFR individuals were identified by PC1-PC4 from 1000G and k-means clustering.	UKB	—
PSS012056	Linked cancer registry records were used to identify participants diagnosed with incident malignant neoplasm of the prostate (ICD-10 code: C61; ICD-9 code: 185) within five years of prediction baseline.	—	184,010 individuals [ 3,133 cases , 180,877 controls ] , 100.0 % Male samples	European	EUR individuals were identified by PC1-PC4 from 1000G and k-means clustering.	UKB	—
PSS012057	Linked cancer registry records were used to identify participants diagnosed with incident malignant neoplasm of the prostate (ICD-10 code: C61; ICD-9 code: 185) within five years of prediction baseline.	—	5,097 individuals [ 30 cases , 5,067 controls ] , 100.0 % Male samples	South Asian	SAS individuals were identified by PC1-PC4 from 1000G and k-means clustering.	UKB	—

Publication Information (EuropePMC)
Title	Polygenic risk scores for prostate cancer: Comparative evaluations in UK and Australian cohorts.
PubMed ID	40629691(Europe PMC)
doi	10.1016/j.xhgg.2025.100477
Publication Date	July 7, 2025
Journal	*HGG Adv*
Author(s)	Tanha HM, Law MH, Ingold N, Ly P, Olsen CM, Pandeya N, Smith DP, MacInnis RJ, Whiteman DC, Cust AE, Steinberg J.

PGS Publication: PGP000741

Associated Polygenic Score(s)

PGS Developed By This Publication

Performance Metrics

Evaluated Samples